Trials / Completed
CompletedNCT02776163
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas of Head and Neck, A Non-Randomized, Phase II Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nedaplatin | nedaplatin 35mg/m\^2，D1-2，2 cycles |
| DRUG | Docetaxel | Docetaxel 70mg/m\^2，D1，2 cycles |
| RADIATION | Intensity-modulated radiotherapy | a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
- First posted
- 2016-05-18
- Last updated
- 2024-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02776163. Inclusion in this directory is not an endorsement.